The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS SUMMARY: Goldman Likes John Wood; Peel Cuts YouGov

Fri, 31st Jul 2020 09:47

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday afternoon:

----------

FTSE 100

----------

CREDIT SUISSE CUTS SHELL PRICE TARGET TO 1,600 (1,700) PENCE - 'OUTPERFORM'

----------

BERENBERG RAISES SHELL B PRICE TARGET TO 1,450 (1,440) PENCE - 'HOLD'

----------

BERENBERG CUTS LLOYDS PRICE TARGET TO 30 (35) PENCE - 'HOLD'

----------

BARCLAYS RAISES SCHRODERS PRICE TARGET TO 2,920 (2,790) PENCE - 'EQUAL WEIGHT'

----------

BERENBERG RAISES SCHRODERS PRICE TARGET TO 3,200 (2,203) PENCE - 'HOLD'

----------

BARCLAYS RAISES 3I GROUP PRICE TARGET TO 1,200 (1,120) PENCE - 'OVERWEIGHT'

----------

JEFFERIES CUTS RSA INSURANCE PRICE TARGET TO 580 (600) PENCE - 'BUY'

----------

JPMORGAN RAISES INTERTEK PRICE TARGET TO 5,900 (5,200) PENCE - 'OVERWEIGHT'

----------

GOLDMAN RAISES AVEVA GROUP PRICE TARGET TO 4,600 (4,100) PENCE - 'NEUTRAL'

----------

GOLDMAN RAISES AVEVA GROUP PRICE TARGET TO 4,600 (4,100) PENCE - 'NEUTRAL'

----------

GOLDMAN SACHS CUTS BAE SYSTEMS PRICE TARGET TO 505 (514) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS BAE SYSTEMS PRICE TARGET TO 750 (765) PENCE - 'OVERWEIGHT'

----------

GOLDMAN SACHS RAISES MELROSE INDUSTRIES PRICE TARGET TO 105 PENCE - 'NEUTRAL'

----------

BARCLAYS RAISES RENTOKIL INITIAL PRICE TARGET TO 573 (446) PENCE - 'OVERWEIGHT'

----------

JPMORGAN CUTS COMPASS GROUP PRICE TARGET TO 1,000 (1,050) PENCE - 'UNDERWEIGHT'

----------

GOLDMAN SACHS CUTS COMPASS GROUP PRICE TARGET TO 1,310 (1,400) PENCE - 'BUY'

----------

GOLDMAN SACHS CUTS GLAXOSMITHKLINE PRICE TARGET TO 2,020 (2,060) PENCE - 'BUY'

----------

DZ BANK CUTS FAIR VALUE FOR GLAXOSMITHKLINE TO 1,850 (1,900) PENCE - 'BUY'

----------

DZ BANK RAISES FAIR VALUE FOR ASTRAZENECA TO 7,500 (7,300) PENCE - 'SELL'

----------

FTSE 250

----------

RBC CUTS LANCASHIRE HOLDINGS PRICE TARGET TO 950 (1,050) PENCE - 'OUTPERFORM'

----------

CREDIT SUISSE RAISES ULTRA ELECTRONICS PRICE TARGET TO 2,600 (2,550) PENCE - 'OUTPERFORM'

----------

BERENBERG RAISES ULTRA ELECTRONICS PRICE TARGET TO 2,600 (2,300) PENCE - 'BUY'

----------

MORGAN STANLEY RAISES VESUVIUS PRICE TARGET TO 450 (420) PENCE - 'EQUAL-WEIGHT'

----------

RBC RAISES WEIR GROUP PRICE TARGET TO 1,680 (1,420) PENCE - 'OUTPERFORM'

----------

RBC CUTS MORGAN ADVANCED MATERIALS TARGET TO 265 (275) PENCE - 'SECTOR PERFORM'

----------

JPMORGAN RAISES BODYCOTE PRICE TARGET TO 670 (590) PENCE - 'NEUTRAL'

----------

GOLDMAN SACHS RAISES JOHN WOOD GROUP TO 'BUY' ('NEUTRAL')

----------

JEFFERIES RAISES DRAX GROUP PRICE TARGET TO 280 (170) PENCE - 'HOLD'

----------

BERENBERG CUTS GREENCORE PRICE TARGET TO 200 (210) PENCE - 'BUY'

----------

JPMORGAN RAISES B&M PRICE TARGET TO 430 (360) PENCE - 'NEUTRAL'

----------

OTHER MAIN MARKET AND AIM

----------

PEEL HUNT CUTS YOUGOV TO 'HOLD' (ADD) - PRICE TARGET 700 PENCE

----------

BERENBERG RAISES YOUGOV PRICE TARGET TO 920 (610) PENCE - 'BUY'

----------

RBC CUTS TED BAKER PRICE TARGET TO 70 (140) PENCE - 'UNDERPERFORM'

----------

LIBERUM CUTS FULLER SMITH & TURNER PRICE TARGET TO 700 (820) PENCE - 'HOLD'

----------

LIBERUM CUTS ROBERT WALTERS PRICE TARGET TO 535 (540) PENCE - 'BUY'

----------

BERENBERG RAISES CERES POWER PRICE TARGET TO 580 (470) PENCE - 'BUY'

----------

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.